Valneva's Shigella vaccine meets primary endpoint in Phase 2 trial
VALN•Valneva said its S4V2 Shigella vaccine candidate met the primary endpoint in an adult Phase 2 challenge trial, while an infant trial showed immune responses against all four targeted serotypes.
1. Trial results
Valneva announced positive results from two Phase 2 trials of S4V2. The adult challenge trial met its primary endpoint, reducing shigellosis versus placebo; infant results showed antibodies against all four targeted serotypes remained above baseline six months later.
2. Next steps
Both trials showed favorable safety profiles. Full datasets are under review to guide further clinical development, including dose selection and vaccination schedules.
